Top

Journal of Cardiovascular Translational Research

Published in:

01-08-2013

Positioning of Inflammatory Biomarkers in the Heart Failure Landscape

Authors: Justin Hartupee, Douglas L. Mann

Published in: Journal of Cardiovascular Translational Research | Issue 4/2013

Abstract

The clinical syndrome of heart failure is characterized by a systemic inflammatory response that contributes to end organ damage in the heart and circulation and can thus lead to worsening heart failure. The ensemble of inflammatory mediators that have been detected in heart failure patients include pro-inflammatory cytokines and their cognate receptors, as well as molecules secreted/released by macrophages (galectin-3 and pentraxin-3). Inflammatory biomarkers correlate with disease severity and prognosis across the broad spectrum of heart failure syndromes. Given the proliferation of new biomarkers that predict disease severity and prognosis in heart failure, it is reasonable to ask whether there is a current role for measuring inflammatory mediators in heart failure. This review will attempt to address this question, as well as review several novel approaches that have utilized inflammatory biomarkers to enhance risk stratification and prognosis in heart failure patients.

Askevold, E. T., Nymo, S., Ueland, T., Gravning, J., Wergeland, R., Kjekshus, J., et al. (2013). Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circulation Heart Failure, 6, 91–98.PubMedCrossRef

Bozkurt, B., Mann, D. L., & Deswal, A. (2010). Biomarkers of inflammation in heart failure. Heart Failure Reviews, 15, 331–341.PubMedCrossRef

Chin, B. S., Conway, D. S., Chung, N. A., Blann, A. D., Gibbs, C. R., & Lip, G. Y. (2003). Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: Relationship to treatment and prognosis. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis, 14, 515–521.CrossRef

Deswal, A., Petersen, N. J., Feldman, A. M., Young, J. B., White, B. G., & Mann, D. L. (2001). Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation, 103, 2055–2059.PubMedCrossRef

Doroudgar, S., & Glembotski, C. C. (2011). The cardiokine story unfolds: Ischemic stress-induced protein secretion in the heart. Trends in Molecular Medicine, 17, 207–214.PubMedCrossRef

Dunlay, S. M., Weston, S. A., Redfield, M. M., Killian, J. M., & Roger, V. L. (2008). Tumor necrosis factor-alpha and mortality in heart failure: A community study. Circulation, 118, 625–631.PubMedCrossRef

Gallucci, S., & Matzinger, P. (2001). Danger signals: SOS to the immune system. Current Opinion in Immunology, 13, 114–119.PubMedCrossRef

Gullestad, L., Ueland, T., Kjekshus, J., Nymo, S. H., Hulthe, J., Muntendam, P., et al. (2012). The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). American Heart Journal, 164, 878–883.PubMedCrossRef

Gullestad, L., Ueland, T., Vinge, L. E., Finsen, A., Yndestad, A., & Aukrust, P. (2012). Inflammatory cytokines in heart failure: Mediators and markers. Cardiology, 122, 23–35.PubMedCrossRef

10.

Ionita, M. G., Arslan, F., de Kleijn, D. P., & Pasterkamp, G. (2010). Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease. Journal of Innate Immunity, 2, 307–315.PubMedCrossRef

11.

Jacobshagen, C., Belardinelli, L., Hasenfuss, G., & Maier, L. S. (2011). Ranolazine for the treatment of heart failure with preserved ejection fraction: Background, aims, and design of the RALI-DHF study. Clinical Cardiology, 34, 426–432.PubMedCrossRef

12.

Januzzi, J. L., Jr., Peacock, W. F., Maisel, A. S., Chae, C. U., Jesse, R. L., Baggish, A. L., et al. (2007). Measurement of the interleukin family member ST2 in patients with acute dyspnea: Results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. Journal of the American College of Cardiology, 50, 607–613.PubMedCrossRef

13.

Kalogeropoulos, A., Georgiopoulou, V., Psaty, B. M., Rodondi, N., Smith, A. L., Harrison, D. G., et al. (2010). Inflammatory markers and incident heart failure risk in older adults: The Health ABC (Health, Aging, and Body Composition) study. Journal of the American College of Cardiology, 55, 2129–2137.PubMedCrossRef

14.

Ky, B., French, B., Levy, W. C., Sweitzer, N. K., Fang, J. C., Wu, A. H., et al. (2012). Multiple biomarkers for risk prediction in chronic heart failure. Circulation. Heart Failure, 5, 183–190.PubMedCrossRef

15.

Ky, B., French, B., McCloskey, K., Rame, J. E., McIntosh, E., Shahi, P., et al. (2011). High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circulation. Heart Failure, 4, 180–187.PubMedCrossRef

16.

Latini, R., Gullestad, L., Masson, S., Nymo, S. H., Ueland, T., Cuccovillo, I., et al. (2012). Pentraxin-3 in chronic heart failure: The CORONA and GISSI-HF trials. European Journal of Heart Failure, 14, 992–999.PubMedCrossRef

17.

Levine, B., Kalman, J., Mayer, L., Fillit, H. M., & Packer, M. (1990). Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. The New England Journal of Medicine, 223, 236–241.CrossRef

18.

Levine, S. J. (2008). Molecular mechanisms of soluble cytokine receptor generation. The Journal of Biological Chemistry, 283, 14177–14181.PubMedCrossRef

19.

Luft, F. C. (2001). Angiotensin, inflammation, hypertension, and cardiovascular disease. Current Hypertension Reports, 3, 61–67.PubMedCrossRef

20.

Mann, D. L. (1996). Stress activated cytokines and the heart. Cytokine & Growth Factor Reviews, 7, 341–354.CrossRef

21.

Mann, D. L. (2002). Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circulation Research, 91, 988–998.PubMedCrossRef

22.

Mann, D. L. (2011). The emerging role of innate immunity in the heart and vascular system: For whom the cell tolls. Circulation Research, 108, 1133–1145.PubMedCrossRef

23.

Manzano-Fernandez, S., Mueller, T., Pascual-Figal, D., Truong, Q. A., & Januzzi, J. L. (2011). Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. The American Journal of Cardiology, 107, 259–267.PubMedCrossRef

24.

Matsubara, J., Sugiyama, S., Nozaki, T., Sugamura, K., Konishi, M., Ohba, K., et al. (2011). Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. Journal of the American College of Cardiology, 57, 861–869.PubMedCrossRef

25.

Matsumoto, M., Tsujino, T., Lee-Kawabata, M., Naito, Y., Sakoda, T., Ohyanagi, M., et al. (2010). Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction. Cytokine, 49, 264–268.PubMedCrossRef

26.

Mueller, C., Laule-Kilian, K., Christ, A., Brunner-La Rocca, H. P., & Perruchoud, A. P. (2006). Inflammation and long-term mortality in acute congestive heart failure. American Heart Journal, 151, 845–850.PubMedCrossRef

27.

Navarro-Gonzalez, J. F., Mora, C., Muros, M., Jarque, A., Herrera, H., & Garcia, J. (2008). Association of tumor necrosis factor-alpha with early target organ damage in newly diagnosed patients with essential hypertension. Journal of Hypertension, 26, 2168–2175.PubMedCrossRef

28.

Pieske, B., Maier, L. S., Bers, D. M., & Hasenfuss, G. (1999). Ca²⁺ handling and sarcoplasmic reticulum Ca²⁺ content in isolated failing and nonfailing human myocardium. Circulation Research, 85, 38–46.PubMedCrossRef

29.

Rauchhaus, M., Doehner, W., Francis, D. P., Davos, C., Kemp, M., Liebenthal, C., et al. (2000). Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation, 102, 3060–3067.PubMedCrossRef

30.

Rehman, S. U., Mueller, T., & Januzzi, J. L., Jr. (2008). Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. Journal of the American College of Cardiology, 52, 1458–1465.PubMedCrossRef

31.

Reichlin, T., Socrates, T., Egli, P., Potocki, M., Breidthardt, T., Arenja, N., et al. (2010). Use of myeloperoxidase for risk stratification in acute heart failure. Clinical Chemistry, 56, 944–951.PubMedCrossRef

32.

Shah, R. V., Chen-Tournoux, A. A., Picard, M. H., van Kimmenade, R. R., & Januzzi, J. L. (2010). Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. European Journal of Heart Failure, 12, 826–832.PubMedCrossRef

33.

Subramanian, D., Subramanian, V., Deswal, A., & Mann, D. (2011). New predictive models of heart failure mortality using time-series measurements and ensemble models. Circulation: Heart Failure, 4, 456–462.

34.

Suzuki, S., Takeishi, Y., Niizeki, T., Koyama, Y., Kitahara, T., Sasaki, T., et al. (2008). Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. American Heart Journal, 155, 75–81.PubMedCrossRef

35.

Torre-Amione, G., Kapadia, S., Benedict, C. R., Oral, H., Young, J. B., & Mann, D. L. (1996). Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD). Journal of the American College of Cardiology, 27, 1201–1206.PubMedCrossRef

36.

Torre-Amione, G., Kapadia, S., Lee, J., Bies, R. D., Lebovitz, R., & Mann, D. L. (1995). Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation, 92, 1487–1493.PubMedCrossRef

37.

Tsutamoto, T., Wada, A., Ohnishi, M., Tsutsui, T., Ishii, C., Ohno, K., et al. (2004). Transcardiac increase in tumor necrosis factor-alpha and left ventricular end-diastolic volume in patients with dilated cardiomyopathy. European Journal of Heart Failure, 6, 173–180.PubMedCrossRef

38.

Ueland, T., Aukrust, P., Damas, J. K., Gullestad, L., & Yndestad, A. (2006). The tumor necrosis factor superfamily in heart failure. Future Cardiology, 2, 101–111.PubMedCrossRef

39.

van Kimmenade, R. R., Januzzi, J. L., Jr., Ellinor, P. T., Sharma, U. C., Bakker, J. A., Low, A. F., et al. (2006). Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. Journal of the American College of Cardiology, 48, 1217–1224.PubMedCrossRef

40.

Vasan, R. S., Sullivan, L. M., Roubenoff, R., Dinarello, C. A., Harris, T., Benjamin, E. J., et al. (2003). Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation, 107, 1486–1491.PubMedCrossRef

41.

Villacorta, H., Masetto, A. C., & Mesquita, E. T. (2007). C-reactive protein: An inflammatory marker with prognostic value in patients with decompensated heart failure. Arquivos Brasileiros de Cardiologia, 88, 585–589.PubMedCrossRef

42.

Wang, T. J., Wollert, K. C., Larson, M. G., Coglianese, E., McCabe, E. L., Cheng, S., et al. (2012). Prognostic utility of novel biomarkers of cardiovascular stress: The Framingham Heart Study. Circulation, 126, 1596–1604.PubMedCrossRef

43.

Weinberg, E. O., Shimpo, M., Hurwitz, S., Tominaga, S., Rouleau, J. L., & Lee, R. T. (2003). Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation, 107, 721–726.PubMedCrossRef

Title: Positioning of Inflammatory Biomarkers in the Heart Failure Landscape
Authors: Justin Hartupee
Douglas L. Mann
Publication date: 01-08-2013
Publisher: Springer US
Published in: Journal of Cardiovascular Translational Research / Issue 4/2013
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-013-9467-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Positioning of Inflammatory Biomarkers in the Heart Failure Landscape

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Multi-Ligand Poly(l-Lactic-co-Glycolic Acid) Nanoparticles Inhibit Activation of Endothelial Cells

Erratum to: Early Results of Sarcomeric Gene Screening from the Egyptian National BA-HCM Program

Development of a Swine Model of Left Bundle Branch Block for Experimental Studies of Cardiac Resynchronization Therapy

Percutaneous Approaches for Efficient Cardiac Gene Delivery

Biomarkers of Diastolic Dysfunction and Myocardial Fibrosis: Application to Heart Failure with a Preserved Ejection Fraction

Heart Failure Biomarkers